Abbott and Medtronic Reach Agreement on Global Patent Disputes

Abbott and Medtronic Reach Agreement on Global Patent Disputes

July 27, 2009

Abbott Park, Illinois (NYSE: ABT) - Abbott announced today a settlement resolving all outstanding intellectual property litigation between the two parties.

Under the terms of the settlement, Medtronic will pay Abbott $400 million. The settlement also includes a mutual agreement not to pursue additional litigation on current and future vascular products, subject to specific conditions and time limits. Additional terms of the agreement were not disclosed.

The one-time impact of this settlement will be treated as a specified item in the third quarter earnings.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.